Travere Therapeutics Inc. (TVTX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Travere Therapeutics Inc. (TVTX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

17.05

-1.54 (-8.28%)

At close: Jan 14, 2025, 3:59 PM

17.10

0.29%

After-hours Jan 14, 2025, 06:10 PM EST

undefined% (undefined)

Bid	16.75
Market Cap	1.48B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-4.52
PE Ratio (ttm)	-3.77
Forward PE	n/a
Analyst	Buy

Ask	27.14
Volume	1,005,599
Avg. Volume (20D)	1,277,518
Open	18.76
Previous Close	18.59
Day's Range	16.80 - 18.76
52-Week Range	5.12 - 20.33
Beta	undefined

About TVTX

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzy...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 8, 2012

Employees 380

Stock Exchange NASDAQ

Ticker Symbol TVTX

Website https://www.travere.com

Analyst Forecast

According to 12 analyst ratings, the average rating for TVTX stock is "Buy." The 12-month stock price forecast is $22, which is an increase of 29.03% from the latest price.

Buy 83.33%

Hold 8.33%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Travere Therapeutics Inc. is scheduled to release its earnings on Feb 13, 2025, during market hours.
Analysts project revenue of $65.57M, reflecting a 45.52% YoY growth and earnings per share of -0.62, making a -34.04% decrease YoY.

Why Price Moved

3 months ago · Source

+15.65%

Travere Therapeutics shares are trading higher aft... Unlock content with Pro Subscription

3 months ago · Source

+3.44%

Travere Therapeutics shares are trading lower after the company announced a voluntary pause of enrollment in its Phase 3 HARMONY study of Pegtibatinase.

News

1 week ago · zacks.com

Wall Street Analysts Believe Travere (TVTX) Could Rally 42.56%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 42.6% in Travere (TVTX). While the effectiveness of this highly sought-after metric is questionable, the positi...

3 weeks ago · seekingalpha.com

Travere Therapeutics: Cautiously Bullish Based On Improving Revenue

Travere Therapeutics' sparsentan received full FDA approval for IgA nephropathy, showing long-term kidney function preservation and significant market growth, with $35mn in 3Q24 revenues. Despite setb...

2 months ago · marketbeat.com

3 Under-the-Radar Healthcare Companies

The healthcare sector is vast and includes everything from massive legacy companies including UnitedHealth Group Inc. NYSE: UNH and McKesson Corp. NYSE: MCK to tiny upstart pharmaceuticals firms. Inve...

2 months ago · seekingalpha.com

Travere Therapeutics, Inc. (TVTX) Q3 2024 Earnings Call Transcript

Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Nivi Nehra - Vice President of Corporate Communications and Investor Relatio...

2 months ago · zacks.com

Travere (TVTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street esti...

2 months ago · zacks.com

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates

Travere Therapeutics (TVTX) came out with a quarterly loss of $0.70 per share in line with the Zacks Consensus Estimate. This compares to loss of $1.17 per share a year ago.

2 months ago · zacks.com

Wall Street Analysts See a 26.27% Upside in Travere (TVTX): Can the Stock Really Move This High?

The mean of analysts' price targets for Travere (TVTX) points to a 26.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts...